CGRP and headache: a brief review

Author:

Tepper Stewart J.

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Neurology (clinical),Dermatology,General Medicine

Reference40 articles.

1. Edvinsson L (2005) Clinical data on the CGRP antagonist BIBN4096BS for treatment of migraine attacks. CNS Drug Rev 11:69–76

2. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM, BIBN 4096 BS Clinical Proof of Concept Study Group (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104–1110

3. Lipton RB, Coric V, Stock EG, Stock D, Morris BA, McCormack T, Frost M, Gentile K, Conway CM, Croop R (2018) Efficacy, safety, and tolerability of rimegepant 75 mg, an oral CGRP receptor antagonist, for the acute treatment of migraine: results from a double-blind, randomized, placebo-controlled trial, Study 301. Poster PS123LB. Late breaking abstracts, American Headache Society 60th scientific meeting, San Francisco, CA, June 2018. Headache 58:1336–1337 (abstract)

4. Lipton RB, Coric V, Stock EG, Stock D, Morris BA, McCormack T, Frost M, Gentile K, Conway CM, Croop R (2018) Efficacy, safety, and tolerability of rimegepant 75 mg, an oral CGRP receptor antagonist, for the acute treatment of migraine: results from a double-blind, randomized, placebo-controlled trial, Study 302. Poster IOR-02LB. Late breaking abstracts, American Headache Society 60th scientific meeting, San Francisco, CA, June 2018. Headache 58:1289 (abstract)

5. Lipton RB, Dodick DW, Ailani J, Lu K, Lakkis H, Finnegan M, Szegedi A, Trugman JM (2018) Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: results from a single attack phase III study, ACHIEVE II. Poster PS111B. Late breaking abstracts, American Headache Society 60th scientific meeting, San Francisco, CA, June 2018. Headache 58:1315–1316 (abstract)

Cited by 46 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3